La cadena de opciones muestra datos clave de las opciones de acciones de Meridian a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Meridian..

Meridian (NASDAQ:MRBK) Bolsa, Cadena de Opciones

Meridian

Meridian Corp is a full-service, state-chartered commercial bank providing personal, business lending, and deposit services. It operates in three business segments including Bank, Wealth, and Mortgage. It generates maximum revenue from the Bank segment that consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans, resulting in the generation of net interest income, and other sources.

EVAX

IDAI

INTZ

LIDR

LKCO

LUXH

MGIH

MLGO

MRBK

MTRX

NEUP

ONDS

QRHC

RVSN

SLDP

VIRX

WTBA

Descubre las acciones que lideran los movimientos en la apertura del mercado, incluyendo repuntes destacados y caídas sorprendentes.

Acciones de Evaxion Biotech (EVAX) suben alrededor del 62%; 20 acciones que se mueven en el premercado

Meridian Corp

Additionally, divestiture streamlines operations, reducing headcount by approximately 33% and eliminating $20 million in annual operating losses.

News

Guidance

MASS

908 Devices Now Expects To Achieve Adjusted EBITDA Positivity By Q4 2025 And Cash Flow Positivity In 2026

This significant milestone demonstrates the U.S. government's long-standing support of quantum computing and networking
IonQ once again demonstrates its ability to deliver innovative quantum computing and networking systems to customers and partners worldwide

EXTR

Extreme Networks Becomes Official Wi-Fi And Analytics Provider For USL, Transforming Soccer Stadium Connectivity

Nordstrom, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) will release its fourth-quarter financial results, after the <a href="https://www.benzinga.com/quote/JWN/earnings">closing bell, on Tuesday, March 4</a>.
Analysts expect the Seattle, Washington-based company to report quarterly earnings at 93 cents per share, down from 96 cents per share in the year-ago period. Ross Stores projects quarterly revenue of $4.33 billion, compared to $4.42 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Feb. 26, Nordstrom reported that its board of directors approved a quarterly dividend of 19 cents per share.
Nordstrom shares fell 0.2% to close at $24.24 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/JWN/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Evercore ISI Group analyst Michael Binetti maintained an In-Line rating and raised the price target from $22 to $24 on Jan. 13, 2025. This analyst has an accuracy rate of 63%.</li>
<li>UBS analyst Jay Sole upgraded the stock from Sell to Neutral and increased the price target from $14.5 to $24 on Jan. 10, 2025. This analyst has an accuracy rate of 70%.</li>
<li>B of A Securities analyst Lorraine Hutchinson maintained an Underperform rating and raised the price target from $20 to $22 on Nov. 27, 2024. This analyst has an accuracy rate of 67%.</li>
<li>Citigroup analyst Paul Lejuez maintained a Neutral rating and increased the price target from $22 to $23 on Nov. 19, 2024. This analyst has an accuracy rate of 65%.</li>
<li>JP Morgan analyst Matthew Boss maintained an Underweight rating and increased the price target from $19 to $20 on Aug. 28, 2024. This analyst has an accuracy rate of 67%.</li>
</ul>
Considering buying JWN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="443" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04055202/image-14-1024x443.png" alt="" class="wp-image-807808" style="width:615px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04055202/image-14-1024x443.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04055202/image-14-300x130.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04055202/image-14-768x332.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04055202/image-14.png 1462w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44083539/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-yields-3"> </a>
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44083539/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a></li>
</ul>

Earnings

Price Target

Markets

Analyst Ratings

Trading Ideas

Top Wall Street Forecasters Revamp Nordstrom Price Expectations Ahead Of Q4 Earnings

Barclays analyst Nicholas Campanella maintains Portland Gen Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) with a Equal-Weight and raises the price target from $42 to $47.

Barclays Maintains Equal-Weight on Portland Gen Electric, Raises Price Target to $47

Full year 2025 reported revenues are expected to be $54 million to $56 million, inclusive of approximately $1 million of desktop revenues in the first quarter, prior to divestiture.
Management expects further acceleration above 20% in 2026, driven by three defined catalysts: the need for equipment modernization, the launch of the next-gen MX908 mass spec, and the anticipated full-rate production award for the Department of Defense's AVCAD program.

908 Devices Expects 2025 Revenues From Cont Ops Of $53M - $55M, Representing 11% - 15% YoY Growth; Expects Further Acceleration Above 20% In 2026

Barclays analyst Nicholas Campanella maintains Talen Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLN#NASDAQ">TLN</a>) with a Overweight and lowers the price target from $293 to $282.

Barclays Maintains Overweight on Talen Energy, Lowers Price Target to $282

IONQ

IonQ Announced It Has Delivered And Commissioned Quantum Networking System Optimized For Research And Development To The U.S. Air Force Research Laboratory In Rome, New York

Barclays analyst Nicholas Campanella maintains Hawaiian Electric Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HE#NYSE">HE</a>) with a Equal-Weight and raises the price target from $10 to $11.

Barclays Maintains Equal-Weight on Hawaiian Electric Indus, Raises Price Target to $11

Evolution Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPM#NYSE">EPM</a>) ("Evolution" or the "Company") today announced that it has entered into a definitive agreement to acquire non-operated oil and natural gas assets in New Mexico, Texas, and Louisiana (the "Acquisition"). The total purchase price for the Acquisition is $9.0 million, subject to customary closing adjustments. The Acquisition is expected to close by the end of Evolution's third quarter of fiscal 2025 with an effective date of February 1, 2025. The Company intends to finance the Acquisition through a combination of cash on hand and borrowings under its existing credit facility.
Kelly Loyd, President and Chief Executive Officer, commented: "This Acquisition marks our 7th such transaction in the last 6 years and is another step forward in strengthening our production base – aligns with our disciplined growth strategy by adding high-quality, low-decline production at an attractive valuation, estimated at ~2.8x NTM2 Adjusted EBITDA1 which doesn't include any incremental cash flows for upside opportunities. These assets complement our existing portfolio and enhance our ability to generate stable free cash flow, which supports our long-standing commitment to returning capital to shareholders. We see additional upside through reactivations of existing waterfloods and through operational efficiencies, which will further enhance long-term value."
The Acquisition expands Evolution's diverse asset portfolio with approximately 440 barrels of oil equivalent per day (BOEPD) of net production, consisting of a balanced commodity mix of 60% oil and 40% natural gas. The acquired assets are primarily low-decline, Proved Developed Producing (PDP) properties, characterized by a sub-7% annual base decline, ensuring stable cash flows and long-term value creation. The transaction is immediately accretive to all key metrics, reinforcing Evolution's ability to sustain and grow its shareholder returns. The portfolio consists of approximately 254 gross producing wells across all regions. The assets will be managed by a top-tier private operator, ensuring operational efficiency and the ability to maximize value.

Evolution Petroleum Acquires $9M Oil and Gas Assets, Expands Production in New Mexico, Texas, and Louisiana

908 Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASS#NASDAQ">MASS</a>) reported quarterly sales of $18.82 million which beat the analyst consensus estimate of $16.39 million by 14.85 percent. This is a 31.14 percent increase over sales of $14.35 million the same period last year.

Earnings Beats

908 Devices Q4 Sales $18.82M Beat $16.39M Estimate

This approval marks a significant milestone in emissions management, empowering operators to integrate AOGI into their emissions monitoring programs to detect and locate fugitive methane emissions with unmatched efficiency and precision.

ChampionX's Aerial Optical Gas Imaging (AOGI) Platform Earns EPA Approval

General

Redwire Bags Study Contract By The European Space Agency (ESA) To Conceptualize A spacecraft Platform For Mars

Barclays analyst Nicholas Campanella maintains Ameren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>) with a Equal-Weight and raises the price target from $95 to $102.

Barclays Maintains Equal-Weight on Ameren, Raises Price Target to $102

Wellgistics Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGRX#NASDAQ">WGRX</a>, the ", Company", ))), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced that its wholly owned subsidiary, Wellgistics LLC, is collaborating with Protega Pharmaceuticals Inc. ("Protega"). Protega is the innovative specialty pharmaceutical company that launched ROXYBOND&#x2122; (oxycodone hydrochloride), the first and only FDA-approved abuse-deterrent immediate-release (IR) opioid pain medication in the U.S. The collaboration is meant to support pharmacist education on abuse-deterrent pain management options and regulatory compliance as well as increase patient access to ROXYBOND&#x2122; for appropriately prescribed patients.
Wellgistics LLC is a pharmaceutical wholesaler and National Association of Boards of Pharmacy ("NABP") authorized distributor that serves over 5,400 independent pharmacies across all 50 states. The relationship will support education to these pharmacies and help provide distribution of ROXYBOND&#x2122; to appropriately prescribed patients, particularly in underserved and rural areas where Wellgistics LLC's independent pharmacy clients play a critical role in patient care.

WGRX

Wellgistics Partners with Protega to Expand Access to Abuse-Deterrent Opioid Pain Medication, Support Pharmacist Education, Distribute ROXYBOND to Independent Pharmacies Nationwide

FROG

JFrog Launched Secure AI Model Delivery Accelerated By NVIDIA NIM Microservices

On Tuesday, the Israeli Ministry of Health and the Institutional Review Board (IRB) approved MIRA Pharmaceuticals, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) Phase 1 trial for Ketamir-2, the company's novel oral ketamine analog in development for neuropathic pain.
In December, MIRA Pharmaceuticals submitted an Investigational New Drug (IND) application to the FDA to start <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42576911/exclusive-mira-pharmaceuticals-files-fda-application-to-start-human-trials-for-its-lead-pain-treatment" rel="noreferrer noopener">human trials for Ketamir-2</a>.
MIRA's preclinical studies demonstrate Ketamir-2's superior efficacy, safety, and optimized pharmacokinetics, supporting its advancement into Phase 1 clinical trials.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42411562/exclusive-mira-pharmaceuticals-validates-ketamir-2s-safety-profile-paving-way-for-human-trials-in-neuropathic-pain" rel="noreferrer noopener">EXCLUSIVE: MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile, Paving Way For Human Trials In Neuropathic Pain</a>
Subject recruitment is scheduled to begin in the first quarter of 2025.
The study will be conducted at the Clinical Pharmacology Unit, Hadassah Medical Center in Jerusalem, Israel.
The Phase 1, randomized, double-blind, placebo-controlled, single-center study evaluates the safety, tolerability, and pharmacokinetics of orally administered Ketamir-2 in healthy adult volunteers.
The trial consists of two parts:
<ul>
<li>Single Ascending Dose (SAD) Part: 32 participants</li>
<li>Multiple Ascending Dose (MAD) Part: 24 participants</li>
</ul>
In addition to assessing the frequency and severity of adverse events (AEs) and serious adverse events (SAEs), the study will closely evaluate ketamine-related behavioral side effects and assess Ketamir-2's distinct pharmacological profile.
The decision to conduct the study in Israel was made to accelerate timelines and optimize costs, allowing Mira to efficiently allocate resources and extend its operational runway.
The company expects Phase 1 to conclude by the fourth quarter of 2025, paving the way for a Phase 2a study in neuropathic pain patients to be initiated by the end of the year.
Neuropathic pain is a rapidly growing market, projected to reach $5.2 billion in North America by 2030.
Beyond neuropathic pain, MIRA Pharmaceuticals is conducting ongoing preclinical studies evaluating Ketamir-2 in post-traumatic stress disorder (PTSD) and a potential topical formulation for localized pain relief.
These additional indications could significantly broaden the clinical and commercial potential of Ketamir-2.
In parallel, the company is assessing Mira-55 for its potential in memory enhancement.
Price Action: MIRA stock traded higher by 7.52% to $0.98 premarket at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44103223/broadcom-debuts-velosky-to-accelerate-5g-and-satellite-adoption" target="_blank" rel="noreferrer noopener">Broadcom Debuts VeloSky To Accelerate 5G And Satellite Adoption</a></li>
</ul>

Biotech

Health Care

Market-Moving Exclusives

Exclusives

MIRA

EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain

EXCLUSIVE: Mira Pharmaceuticals Tells Benzinga Co. Announces Approval And Initiation Of Phase I Clinical Trial For Ketamin-2 In Neuropathic Pain

Barclays analyst Luke Sergott maintains Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) with a Equal-Weight and lowers the price target from $25 to $12.

FTRE

Barclays Maintains Equal-Weight on Fortrea Holdings, Lowers Price Target to $12

LASE

Laser Photonics Announced The Expansion Of Its Laser Drilling Technology Development Program. This Initiative, In Collaboration With Its Subsidiary Control Micro Systems, Inc., Targets The Plastic, Metal And Ceramic Drilling Technology Markets

CTSO

CytoSorbents Delays Earnings Release To Allow Additional Time Tor Annual Audit Completion After Corporate Controller's Passing

Press Releases

Patrick Hart Joins Meridian Bank as SVP, Commercial Lending

Meridian Corporation Reports First Quarter 2024 Results and Announces a Quarterly Dividend of $0.125 per Common Share

Management

Chris McDermott Joins Meridian Bank as SVP, Commercial Lending

Meridian Corporation Reports Second Quarter 2024 Results and Announces a Quarterly Dividend of $0.125 per Common Share

Dividends

Meridian Corporation Reports Third Quarter 2024 Results and Announces a Quarterly Dividend of $0.125 per Common Share

Meridian Corporation Reports Fourth Quarter 2024 Results and Announces a Quarterly Dividend of $0.125 per Common Share

Comments

Meridian

Meridian (MRBK) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL